ROCKVILLE, Md.--(BUSINESS WIRE)--20/20 GeneSystems, Inc. (“20/20” ) announced today at the AdvaMed MedTech Conference in Washington, D.C. that the company has been awarded nearly $3 million in grants from the National Cancer Institute’s (NCI) Small Business Innovative Research (SBIR) Program to develop tests to help oncologists predict the effectiveness of targeted cancer therapies. Over 20 targeted therapies have been approved over the last 10 years but they typically benefit only a subset of patients to whom they are administered. This creates missed opportunities for individual patients who might otherwise have been helped with more effective drugs while wasting hundreds of millions of dollars in unnecessary spending.
